Search results (1320)
« Back to PublicationsA tale of two alleles: TP53 and transformation in MPNs.
Brierley C. and Psaila B., (2022), Blood, 139, 3567 - 3568
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
Follows GA. et al, (2022), Br J Haematol, 197, 558 - 572
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211
PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
Nicum S. and Blagden SP., (2022), Clin Cancer Res, 28, 2201 - 2203
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Vadgama S. et al, (2022), Value Health, 25, 1010 - 1017
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.
Cheng VWT. et al, (2022), Clin Cancer Res, 28, 2385 - 2396
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.
Garg M. et al, (2022), Nat Commun, 13
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J. et al, (2022), Blood, 139, 2931 - 2941
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
Li L. et al, (2022), Blood, 139, 2797 - 2815
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.
Lim SH. et al, (2022), Nat Cancer, 3, 552 - 564
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli ML. et al, (2022), NPJ Breast Cancer, 8
Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison C. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 27 - 28
Longitudinal and Individual Symptom Analyses of Momelotinib and Ruxolitinib-Treated Myelofibrosis Patients from SIMPLIFY-1
Mesa R. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 79 - 80
Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing MANIFEST trial
Curto-Garcia N. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 75 - 76
Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study.
Clift AK. et al, (2022), BMJ Open, 12